Hims faces legal action as FDA restricts compounded weight-loss drugs
The telehealth company is the target of legal claims as federal limits tighten on compounded versions of semaglutide and tirzepatide.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 2 00:17 ETSource: polskieradio.pl
The wire
- 01Hims is facing legal action tied to its compounded weight-loss offerings as the FDA restricts compounding of GLP-1 drugs, the report says.
- 02Telehealth operators and 503A partners selling compounded incretins face direct legal and supply exposure if enforcement broadens.
- 03The report gives little detail on the claims, venue or the FDA's specific restrictions, so the scope of liability remains unclear.
From the source
Read at polskieradio.plhims faces legal action as fda restricts compounded weight-loss drugs
